Seth J Corey

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Targeted therapy: for kids, too
    Seth J Corey
    Division of Pediatrics, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Pediatr Blood Cancer 45:623-34. 2005
  2. ncbi request reprint Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia
    Seth J Corey
    Section of Pediatric Leukemia Lymphoma, Division of Pediatrics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Pediatr Hematol Oncol 27:166-8. 2005
  3. ncbi request reprint New agents in the treatment of childhood leukemias and myelodysplastic syndromes
    Seth J Corey
    Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of Leukemia, University of Texas M D Anderson Cancer Center, Box 853, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 7:399-405. 2005
  4. ncbi request reprint Myelodysplastic syndromes: the complexity of stem-cell diseases
    Seth J Corey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 7:118-29. 2007
  5. pmc G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth
    Quan Sheng Zhu
    Division of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:1847-56. 2006
  6. doi request reprint Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience
    Dolly G Aguilera
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, TX, USA
    J Pediatr Hematol Oncol 31:803-11. 2009
  7. ncbi request reprint Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
    Igor Semenov
    Department of Pediatrics Hematology Oncology, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    Leuk Res 26:271-80. 2002
  8. ncbi request reprint A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
    Yun Dai
    Department of Medicine, Virginia Commonwealth University Medical College of Virginia, Richmond, VA 23298, USA
    J Biol Chem 279:34227-39. 2004

Research Grants

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Targeted therapy: for kids, too
    Seth J Corey
    Division of Pediatrics, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Pediatr Blood Cancer 45:623-34. 2005
    ..With examples drawn from pediatric oncology, the critical steps in the pre-clinical development of targeted therapy are reviewed here...
  2. ncbi request reprint Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia
    Seth J Corey
    Section of Pediatric Leukemia Lymphoma, Division of Pediatrics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Pediatr Hematol Oncol 27:166-8. 2005
    ..After three courses, he attained a remission marrow with 5% blasts and disappearance of the 5q- and 9q- cytogenetic abnormalities...
  3. ncbi request reprint New agents in the treatment of childhood leukemias and myelodysplastic syndromes
    Seth J Corey
    Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of Leukemia, University of Texas M D Anderson Cancer Center, Box 853, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 7:399-405. 2005
    ..Increasingly, molecular profiling will be used to guide the development and application of new drugs...
  4. ncbi request reprint Myelodysplastic syndromes: the complexity of stem-cell diseases
    Seth J Corey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 7:118-29. 2007
    ....
  5. pmc G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth
    Quan Sheng Zhu
    Division of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:1847-56. 2006
    ..These data suggest that the G-CSF-induced Lyn-PI3K-Akt pathway drives ROS production. One beneficial effect of therapeutic targeting of Lyn-PI3K-kinase-Akt cascade is abrogating ROS production...
  6. doi request reprint Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience
    Dolly G Aguilera
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, TX, USA
    J Pediatr Hematol Oncol 31:803-11. 2009
    ..003). Childhood t-MDS/AML has a poor prognosis. Although patients benefited from AML-type induction chemotherapy followed by stem cell transplantation as postremission therapy, effective therapies, and prevention are needed...
  7. ncbi request reprint Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
    Igor Semenov
    Department of Pediatrics Hematology Oncology, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    Leuk Res 26:271-80. 2002
    ..A clinical trial using flavopiridol should be performed in patients with myeloma. Its mechanism of action may involve targets other than the cyclin-dependent kinases...
  8. ncbi request reprint A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
    Yun Dai
    Department of Medicine, Virginia Commonwealth University Medical College of Virginia, Richmond, VA 23298, USA
    J Biol Chem 279:34227-39. 2004
    ....

Research Grants4

  1. Scaffolding Proteins in Macrophage Phagocytosis
    Seth Corey; Fiscal Year: 2006
    ....
  2. PROTEIN TYROSINE KINASES IN LEUKO PROLIF AND APOPTOSIS
    Seth Corey; Fiscal Year: 2002
    ..This NIH K02 award will permit the applicant to supplement his American Cancer Society independent investigator grants and protect his laboratory time to at least 85%, this will solidify his establishment as an independent scientist. ..
  3. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    Seth Corey; Fiscal Year: 2007
    ..These studies will provide rationale for a phase II study using Src inhibitors for subsets of MDS patients. ..